Issue 32, 2024
From the journal:

RSC Advances

Correction: Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors

Yue Dong,a   Min Liu,a   Jian Wang,b   Zhuang Dinga  and  Bin Sun*a  

* Corresponding authors

a Institute of BioPharmaceutical Research, Liaocheng University, 1 Hunan Road, Liaocheng 252000, PR China

b Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China

Abstract

Correction for ‘Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors’ by Yue Dong et al., RSC Adv., 2019, 9, 26302–26314, https://doi.org/10.1039/c9ra03713f.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/D4RA90079K
Article type
Correction
Submitted
11 Jul 2024
Accepted
11 Jul 2024
First published
26 Jul 2024
This article is Open Access
Creative Commons BY license

RSC Adv., 2024,14, 23559-23559

Permissions

Request permissions

Correction: Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors

Y. Dong, M. Liu, J. Wang, Z. Ding and B. Sun, RSC Adv., 2024, 14, 23559 DOI: 10.1039/D4RA90079K

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements